In July 2025, Bryan Johnson told Fortune that Blueprint, the supplement company built on the most documented self-optimization protocol on the planet, had become “a pain in the ass.” He said he was hiring someone else to run it.
The man who turned his own body into a public dataset was negotiating with his own protocol, in front of an audience of founders who had spent three years copying him. Many of them were already done. In 2026 the wellness industry gave their exhaustion a name: bioharmony.
Johnson didn’t need the money. He’d sold Braintree to PayPal for $800 million over a decade earlier, and he told Fortune that selling or shutting Blueprint down “might address the issue.” His line on the whole business: “My goal was never to sell nutrition. It’s the last thing in the world I ever imagined doing.”
The founders watching had bought the ring, the strap, the sauna blanket, the continuous glucose monitor. They’d optimized their sleep until they couldn’t sleep.
Bioharmony is the 2026 wellness shift away from data-driven biohacking toward nervous-system regulation, recovery, and practices measured by how you feel rather than what you score. Where biohacking asks how much you can intervene, bioharmony asks how little you need to.
Last updated: September 2026
Quick answers
What is bioharmony?
Bioharmony is a 2026 wellness approach that prioritizes nervous-system regulation, recovery, and subjective wellbeing over the metrics-driven intervention of biohacking. The Global Wellness Summit describes the shift as one that “prioritizes regulation over results, sensation over scores, and internal coherence over external validation.”
What’s the difference between biohacking and bioharmony?
Biohacking optimizes toward a number using tools, supplements, and tracking devices. Bioharmony removes the number and optimizes toward regulation, using sleep, breathwork, daylight, and rest. Biohacking treats the body as a system to override. Bioharmony treats it as a system to stop interrupting.
Is bioharmony backed by science?
The individual practices are. Nervous-system regulation, sleep consistency, and reduced physiological stress have substantial research behind them. The word “bioharmony” does not. It’s a trend label coined in the spa and wellness industry in late 2025, not a clinical category, and no body certifies it.
What is bioharmony?
Bioharmony is the practice of aligning with your body’s existing regulatory systems instead of overriding them with interventions. The term entered circulation through the spa and wellness trade press: American Spa named “The Rise of Bioharmonization” a headline 2026 trend, crediting Tracy Lee, founder and president of TLEE Spas + Wellness, with framing it as an approach built on “balance over control, drawing from modalities that enhance natural repair, regulate the nervous system, and synchronize the mind, body, and environment.”
That’s trade-press language. Here’s the plainer version: stop measuring, start recovering.
The Global Wellness Summit gave the same idea more institutional weight in its 2026 forecast, where “The Over-Optimization Backlash” runs as the framing trend across a 150-page report covering a wellness economy it puts at $6.8 trillion. Jessica Smith, who wrote that chapter, describes 2026 as the year wellness moves “beyond performance, and the body as perfectible machine, towards emotional repair, nervous-system safety and embodied care.” She’s careful about what the backlash is not: “What’s emerging is not a rejection of science or technology, but a recalibration.”
Recalibration is the operative word for founders. Nobody in this cohort is throwing out the data. They’re throwing out the obligation to act on all of it.
If you want the maximalist version of what’s being recalibrated away from, GJ has already documented it: the $2 million-a-year Blueprint protocol, the peptide boom, and the conference circuit that turned optimization into a status market.
What’s the difference between biohacking and bioharmony?
The difference is the scoreboard. Biohacking requires one. Bioharmony deliberately refuses one, and neurowellness, the third approach now competing for the same founder attention and budget, splits the difference by using hardware to regulate rather than to measure.
Those three are not interchangeable, and founders conflate them constantly.
| Approach | Core goal | Typical tools | Monthly cost | Best for |
|---|---|---|---|---|
| Biohacking | Move a measurable number | Oura, Whoop, CGMs, peptides, supplement stacks | $100 to $2,000+ | Founders with a specific diagnosed problem and the discipline to stop once it’s fixed |
| Bioharmony | Reduce physiological load | Sleep consistency, daylight, breathwork, walking, unstructured rest | Close to $0 | Founders already tracking who feel worse than their numbers say they should |
| Neurowellness | Regulate the nervous system directly | Pulsetto, Elemind, Flow, Mave Health, somatic practice | $30 to $300 | Founders who want the calm without the practice, and accept early-stage evidence |
One practical read of that table: biohacking is a diagnostic phase, not a permanent identity. Bioharmony is what you do after the diagnostics are done.
Why are founders burning out on biohacking?
Because the tracking itself became a source of stress, and there’s now peer-reviewed evidence for it. A study led by Ronan Goel out of the Division of Sleep Medicine at Harvard Medical School, published in the journal SLEEP on May 8, 2026, surveyed 1,280 US adults. It found that 32.4% track their sleep, and among those trackers, 30.9% scored positive for orthosomnia risk, the clinical term for sleep anxiety caused by sleep data. The authors flag that figure as roughly twice the rate of prior estimates.
Read that again with a founder’s eye. Nearly a third of the people paying to improve their sleep are being made anxious by the thing measuring it.
Meanwhile the market kept compounding. Oura raised a $900 million Series E led by Fidelity Management & Research Company at an $11 billion valuation, having sold 3 million rings in 2025, over half of the 5.5 million it has shipped since 2015. Revenue went from $500 million in 2024 to roughly $1 billion in 2025. CEO Tom Hale called it “a global movement toward proactive health.” Both things are true at once: adoption exploded, and satisfaction with what adoption does to your head did not keep pace.
Then the credibility problem. Peter Attia, whose work did more than almost anyone’s to make structured longevity protocols legible to executives, told mindbodygreen he doesn’t believe “there’s a single wearable on the planet that can even come close to” telling you accurately when to exercise or rest. When the person most associated with the protocol says the instruments can’t answer the question, the whole premise of daily readiness scores gets thinner.
Add the founder baseline. The Global Wellness Summit’s neurowellness chapter, written by Heidi Moon, cites Gallup 2025 data showing 40% of people across 144 countries report high daily anxiety, and 36% of UK residents reporting burnout in the past year. Founders are not a calmer subset of that population. GJ’s own reporting on founders training emotional fitness and on Silicon Valley’s longevity obsession tracks the same arc from a different angle.
Where the money is moving
Capital is following regulation, not measurement. The Global Wellness Summit ranked “The Rise of Neurowellness” third in its 2026 trend list, describing a category built on “somatic, self-directed practices that influence the nervous system through conscious control of the body and a new wave of autonomic, tech-driven interventions that regulate the system more directly.”
The hardware is already shipping. Pulsetto and yōjō deliver vagus nerve stimulation, Elemind uses an EEG headband with acoustic stimulation, Mave Health builds a brain-stimulating headset, and Flow, a transcranial direct current stimulation device with FDA clearance, is slated for a US and EU launch in summer 2026. Moon’s chapter notes neurotech startups raising “a few million in VC every couple of weeks.”
The consumer signal is louder than the funding signal. #nervoussystemhealing has passed 230,000 TikTok videos. That’s not a wellness-industry projection, it’s demand that already exists.
For founders building in this space, the arbitrage is obvious and narrow. Biohacking hardware competes with Oura at an $11 billion valuation. Nervous-system products compete against a category where no incumbent owns the definition yet, which is the same structural opening GJ described in its piece on the 2026 backlash against AI slop: when a category over-rotates, the counter-positioning is the opportunity.
The business side of the backlash
The optimization market is going public at exactly the moment its core promise is being questioned, and founders building in wellness should read that timing carefully. Oura filed its S-1 on September 3, 2026, seeking a Nasdaq listing under the ticker OURA, disclosing $1.4 billion in revenue for the year ending June 2026, 74% year-over-year growth, and $59 million in net income. It reported 5 million paid members as of June.
Two lines in that filing matter more than the headline number. Oura conceded it “has only recently achieved profitability” and warned “there can be no assurance that we will maintain profitability in any future period.” It also disclosed that its top two retail customers account for 12% and 10% of revenue respectively, alongside a dependency on third-party AI models and data centers.
Translated: the most successful company in consumer tracking has thin, new profitability, retail concentration risk, and an AI cost structure it doesn’t control. That’s a company priced on subscription retention, and subscription retention is precisely what an over-optimization backlash threatens.
So the founder question isn’t whether tracking is over. Five million paying members says it isn’t. The question is what gets built next to the tracker rather than against it. The GWS report values the wellness economy at $6.8 trillion, and the fastest-moving segment inside it right now isn’t more sensors, it’s interpretation and de-escalation: services that tell you which numbers to ignore.
Pricing is the tell. A sensor company sells hardware plus a monthly subscription. A regulation company sells a practice, which is harder to defend commercially and easier to adopt. Anyone entering this category should decide which side of that line they’re on before writing a deck.
How do you know if you’re over-optimizing?
You’re over-optimizing when the measurement changes your behavior more than the underlying biology does. The Harvard orthosomnia finding is the clinical version of a pattern founders recognize immediately once it’s named.
Five concrete signals, in rough order of how early they show up:
- You check a score before you check how you feel. Reaching for the phone to find out whether you slept well, rather than noticing it, inverts the entire point of the instrument.
- A bad score changes your day. Cancelling a workout or a meeting because a readiness number was low, when you felt fine, means the device is running your calendar.
- Your stack has grown without anything being removed. Supplements, devices, and protocols accumulate. If nothing has been retired in twelve months, you’re collecting, not optimizing.
- You can’t state what problem you’re solving. Attia’s own framing is useful here: a metric should answer a question. Founders who can’t name the question they’re answering are tracking for reassurance.
- The protocol survives evidence against it. When a study or a credible source undercuts something in your routine and you keep it anyway, it stopped being a protocol and became an identity.
The fix is not a new system. Pick one metric worth keeping, set a weekly review, and delete the rest of the notifications. Founders who tried that in 2026 mostly report the same thing, which is that almost nothing in their health actually changed, and the anxiety did.
What a bioharmony week actually looks like
It looks like subtraction. The practical version of bioharmony for a founder is dropping from daily metric review to one weekly check, and reallocating that attention to four inputs that don’t produce a score.
Here’s a version that survives a real calendar:
- One metric, weekly, not daily. Attia’s method is the least intrusive one available: take resting heart rate each morning for two to three weeks to establish a personal baseline, then only act when it jumps five to 10 beats above that. That’s a signal, not a dashboard. Everything else in the app gets ignored.
- Fixed wake time, flexible bedtime. Consistency of wake time does more for circadian stability than chasing a sleep score, and it’s the one variable a founder actually controls when a fundraise or a launch blows up the evening.
- Daylight before screens. Ten to fifteen minutes outside before the first Slack check. Free, unmeasurable, and the single biggest nervous-system input on the list.
- One unstructured block per week. Two hours with no goal, no podcast, no optimization intent. This is the part founders resist hardest, because it produces nothing reportable.
- Breathwork tied to an existing trigger. Five minutes of slow nasal breathing after the last meeting of the day, not as a new habit to maintain but bolted onto one that already exists.
What’s deliberately absent: a new purchase. If adopting bioharmony costs you $400, you’ve bought biohacking with softer marketing. The tell is whether the practice generates a number you check.
Founders with the opposite problem, no protocol at all rather than too much of one, should start with the boring version before the sophisticated one. Sleep and daylight first. GJ’s coverage of building fast in 2026 is a reminder of how compressed founder timelines have become, and compressed timelines are exactly when recovery gets cut first.
Where bioharmony goes wrong
Bioharmony’s biggest risk is that it becomes a premium product category rather than a subtraction. It has no certification body, no clinical definition, and no measurable outcome, which makes it trivially easy to attach to anything with a price tag.
That’s already happening. Jessica Smith’s chapter names On and Nike moving toward sensation-led and recovery-led positioning, and points to Ouronyx, the aesthetic clinic with locations in London and Dubai, as part of the same repositioning. A $600 recovery membership marketed as nervous-system care is not a departure from optimization culture. It’s the same culture with lower lighting.
The second failure mode is discarding data you actually needed. The Harvard finding is about anxiety from tracking, not about tracking being useless. A founder managing a real metabolic or sleep condition should not drop a continuous glucose monitor because a spa trend report said balance is in. Bioharmony is a correction for over-measurement, not a case against measurement.
The third is the vocabulary problem. “Nervous-system regulation” is now doing the work that “hustle” did in 2015: a phrase broad enough to justify whatever the speaker already wanted to do. Skepticism is warranted, in the same way GJ applied it to the signaling economy around founder identity. A protocol that can’t be falsified can’t be evaluated.
The honest summary: bioharmony is a useful correction with a weak evidence base for its brand name and a strong one for its component parts. Use the parts. Ignore the branding. Bryan Johnson, for what it’s worth, didn’t sell Blueprint. He raised money and went all in, which tells you the optimization market isn’t collapsing so much as splitting, and bioharmony is the half that doesn’t need your credit card.
